| Immune suppression in gliomas MM Grabowski, EW Sankey, KJ Ryan, P Chongsathidkiet, SJ Lorrey, ... Journal of neuro-oncology 151, 3-12, 2021 | 208 | 2021 |
| CD4 T-cell exhaustion: does it exist and what are its roles in cancer? AM Miggelbrink, JD Jackson, SJ Lorrey, ES Srinivasan, J Waibl-Polania, ... Clinical Cancer Research 27 (21), 5742-5752, 2021 | 142 | 2021 |
| Anti-CD37 chimeric antigen receptor T cells are active against B-and T-cell lymphomas I Scarfò, M Ormhøj, MJ Frigault, AP Castano, S Lorrey, AA Bouffard, ... Blood, The Journal of the American Society of Hematology 132 (14), 1495-1506, 2018 | 129 | 2018 |
| Chimeric antigen receptor T cells targeting CD79b show efficacy in lymphoma with or without cotargeting CD19 M Ormhøj, I Scarfò, ML Cabral, SR Bailey, SJ Lorrey, AA Bouffard, ... Clinical Cancer Research 25 (23), 7046-7057, 2019 | 74 | 2019 |
| A distinct transcriptional program in human CAR T cells bearing the 4-1BB signaling domain revealed by scRNA-seq AC Boroughs, RC Larson, ND Marjanovic, K Gosik, AP Castano, ... Molecular Therapy 28 (12), 2577-2592, 2020 | 68 | 2020 |
| Targeting PD-L1 initiates effective antitumor immunity in a murine model of Cushing disease HR Kemeny, AA Elsamadicy, SH Farber, CD Champion, SJ Lorrey, ... Clinical Cancer Research 26 (5), 1141-1151, 2020 | 49 | 2020 |
| CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D–NKG2DL axis EC Lerner, KI Woroniecka, VM D’Anniballe, DS Wilkinson, AA Mohan, ... Nature Cancer 4 (9), 1258-1272, 2023 | 34 | 2023 |
| Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12 X Wu, GR Schnitzler, GF Gao, B Diamond, AR Baker, B Kaplan, ... Journal of Biological Chemistry 295 (11), 3431-3446, 2020 | 19 | 2020 |
| Post‐translational modification directs nuclear and hyphal tip localization of Candida albicans mRNA‐binding protein Slr1 C Ariyachet, C Beißel, X Li, S Lorrey, O Mackenzie, PM Martin, K O'Brien, ... Molecular microbiology 104 (3), 499-519, 2017 | 9 | 2017 |
| Engineering an optimized trimeric APRIL-based CAR to broaden targetability of multiple myeloma A Schmidts, M Ormhoj, AO Taylor, SJ Lorrey, I Scarfò, MJ Frigault, ... Blood 132 (Supplement 1), 2059-2059, 2018 | 5 | 2018 |
| Systemic immune derangements are shared across various CNS pathologies and reflect novel mechanisms of immune privilege SJ Lorrey, J Waibl Polania, LP Wachsmuth, A Hoyt-Miggelbrink, ZP Tritz, ... Neuro-Oncology Advances 5 (1), vdad035, 2023 | 3 | 2023 |
| Advances in Treatment of Isocitrate Dehydrogenase (IDH)-Wildtype Glioblastomas HW Sim, S Lorrey, M Khasraw Current Neurology and Neuroscience Reports 23 (6), 263-276, 2023 | 2 | 2023 |
| A Novel MHC-Independent Mechanism of Tumor Cell Killing by CD8+ T Cells E Lerner, K Woroniecka, V D’Anniballe, D Wilkinson, S Lorrey, ... bioRxiv, 2023.02. 02.526713, 2023 | 2 | 2023 |
| Intracranial tumors lead to sequestration of T cells in the bone marrow SJ Lorrey, P Chongsathidkiet, DS Wilkinson, C Champion, P Fecci The Journal of Immunology 204 (1_Supplement), 165.26-165.26, 2020 | 2 | 2020 |
| Rescuing imperfect antigens for immuno-oncology SJ Lorrey, L Sanchez-Perez, PE Fecci Nature Biotechnology 37 (9), 1002-1003, 2019 | 2 | 2019 |
| Immune checkpoint blockade therapy in high-grade glioma JW Polania, S Lorrey, D Wilkinson, PE Fecci Immunotherapeutic Strategies for the Treatment of Glioma, 91-108, 2022 | 1 | 2022 |
| BSCI-07. BONE MARROW T-CELL SEQUESTRATION IN THE SETTING OF BRAIN METASTASES P Chongsathidkiet, K Woroniecka, C Dechant, H Kemeny, X Cui, ... Neurooncol Adv 1 (Suppl 1), i2, 2019 | 1 | 2019 |
| Correction: Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19 M Ormhøj, I Scarfò, ML Cabral, SR Bailey, SJ Lorrey, AA Bouffard, ... Clinical Cancer Research 30 (10), 2286-2286, 2024 | | 2024 |
| Abstract PR-001: Beta-adrenergic blockade licenses the use of immunotherapy in primary brain tumors and brain metastases S Lorrey, L Wachsmuth, M Price, C Neff, Q Ostrom, P Fecci Cancer Research 84 (5_Supplement_1), PR-001-PR-001, 2024 | | 2024 |
| TNFR2 loss leads to decreased TOX expression in T cells without affecting TIM3 and improves responses to tumor and chronic LCMV A Hoyt-Miggelbrink, J Waibl Polania, L Wachsmuth, SJ Lorrey, A Mohan, ... bioRxiv, 2024.07. 12.603311, 2024 | | 2024 |
